PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome

Matera, I; Bachetti, T; Puppo, F; Duca, M; Morandi, F; Casiraghi, G.M.; Cilio, M.R.; Hennekam, R.C.M.; Hofstra, R; Schöber, J.G.; Ravazzolo, R.; Ottonello, G; Ceccherini, I

Published in:
Journal of Medical Genetics

Citation for published version (APA):
PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome

I Matera, T Bachetti, F Puppo, M Di Duca, F Morandi, G M Casiraghi, M R Cilio, R Hennekam, R Hofstra, J G Schöber, R Ravazzolo, G Ottonello and I Ceccherini

doi:10.1136/jmg.2003.015412

Updated information and services can be found at:
http://jmg.bmj.com/cgi/content/full/41/5/373

These include:

References
This article cites 20 articles, 5 of which can be accessed free at:
http://jmg.bmj.com/cgi/content/full/41/5/373#BIBL

21 online articles that cite this article can be accessed at:
http://jmg.bmj.com/cgi/content/full/41/5/373#otherarticles

Rapid responses
You can respond to this article at:
http://jmg.bmj.com/cgi/eletter-submit/41/5/373

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Genetics (3952 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Journal of Medical Genetics go to:
http://www.bmjjournals.com/subscriptions/
**LETTER TO JMG**

**PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome**

I Matera, T Bachetti, F Puppo, M Di Duca, F Morandi, G M Casiraghi, M R Cilio, R Hennekam, R Hofstra, J G Schöber, R Ravazzolo, G Ottonello, I Ceccherini


**C**ongenital Central Hypoventilation syndrome (CCHS (MIM 209880)) is a rare disorder, with fewer than 200 patients currently reported worldwide, characterised by absence of adequate autonomic control of respiration with decreased sensitivity to hypercapnia and hypoxia, in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. Children with CCHS show an adequate ventilation while awake but hypoventilate during sleep. More severely affected children hypoventilate both when awake and during sleep. CCHS has been reported in association with several disorders, among which aganglionic megacolon (Hirschsprung disease, HSCR) and tumours of neural crest origin, reflecting a common molecular pathogenesis sustained by defects of one or more genes that control the correct development of neural crest derived cell lineages.

A genetic aetiology has long been hypothesised for CCHS based on recurrence reported in siblings, in half siblings and in affected children born to women with CCHS.

More recently, a generalised autonomic nervous system (ANS) imbalance has been observed among children with CCHS and an increased incidence of ANS dysfunctions (ANSID) reported among relatives of 56 patients with CCHS, as against relatives of 56 matched controls. A family transmission study has shown that the risk of developing an ANSD symptom including CCHS, regarded as the most severe expression of ANS imbalance, mainly depends on the genotype at a major locus, while significant residual variants could be due to additional minor genes, modifying loci effects or environmental factors.

Genes involved in the ANS development, like the RET proto-oncogene, its ligand GDNF, the Endothelin 3 gene, the Brain Derived Neurotrophic Factor (BDNF) and the RNX genes, have been tested and a few mutations found, showing no cosegregation with the disease phenotype in CCHS families.

The PHOX2B gene encodes a 314 amino acids paired box homeodomain transcription factor which is expressed in the developing hindbrain and peripheral nervous system as well as in all noradrenergic centres and visceral motor and branchiomotor neurones of the cranial nerves. Its expression has also been detected in neuronal groups, such as those involved in the medullary control reflexes of autonomic functions. Two PHOX2B mice have shown lack of intestinal innervation and of all central and peripheral neurones that express noradrenergic traits. Two heterozygous frameshift mutations and 16 polyalanine triplet duplications of 5–9 residues, occurred in a 20 alanine tract in the C terminus of the PHOX2B gene, have been described in a total of 29 patients with CCHS (62%). More recently, a mutation screening of the PHOX2B gene performed in 10 patients has revealed polyalanine expansions in four patients with CCHS and one frameshift mutation in a fifth patient (50%), while 65 polyalanine expansions and one nonsense mutation of the same gene have been detected on a total of 67 patients with CCHS (98.5%). Thus, PHOX2B is confirmed as playing a crucial role in the correct development of the central respiratory control system and appears to be a master regulatory gene of the ANS.

**Key points**

- We have carried out mutation screening of the PHOX2B gene in a set of 27 patients affected with congenital Central Hypoventilation syndrome (CCHS), three of whom showed association with Hirschsprung’s disease (HSCR), and also including three familial cases with affected sibling pairs and three late onset central hypoventilation cases (LOCHS).
- Three heterozygous frameshift mutations, two of which occurred de novo, and 22 in-frame changes leading to 5–13 polyalanine expansions of the PHOX2B gene in 25 out of 27 CCHS patients studied (93%) have been identified. Polyalanine triplet expansion has also been detected in the affected siblings of two familial cases and in two asymptomatic parents, one of whom is the mother of a sporadic case.
- A genotype-phenotype correlation is shown between the size of the PHOX2B expanded allele and the severity of both the respiratory phenotype and associated symptoms, and the age of onset.
- We demonstrate that in individuals heterozygous for length variants of the polyalanine stretch of PHOX2B exon 3, the largest allele is always prone to unsuccessful amplification by DNA polymerase. An improved methodological approach is proposed to avoid misleading in vitro amplification that can cause mistakes in recording individuals’ genotypes.
- PHOX2B is confirmed as the major gene in CCHS pathogenesis. Autosomal dominant inheritance with reduced penetrance is demonstrated.

**Abbreviations:** ANS, autonomic nervous system; ANSD, ANS dysfunctions; CCHS, congenital Central Hypoventilation syndrome; HSCR, Hirschsprung’s disease; LOCHS, late onset Central Hypoventilation syndrome; SNP, single nucleotide polymorphism
Here, we report a mutation screening of the coding region of the \textit{PHOX2B} gene in a total of 27 unrelated patients affected with CCHS, including three familial cases with affected sibling pairs and three cases with late onset CHS (LOCHS). Results support the notion of a simple Mendelian inheritance in CCHS with dominant, incompletely penetrant \textit{PHOX2B} molecular defects recurring in the vast majority of the patients and their families. Moreover, the size of the polyalanine expansions detected correlates with the degree of phenotypic severity.

\section*{METHODS}

\subsection*{Subjects}

We have analysed 27 individuals from Italy, Germany and the Netherlands affected with CCHS, isolated or in association with several autonomic nervous system dysfunctions. Twenty one of them have isolated CCHS, three presented with CCHS and IHSCR, while the other three had a late onset of the disease. Three isolated CCHS cases are familial, showing affected siblings.

The diagnostic criteria of the American Thoracic Society statement on CCHS\textsuperscript{1} were used and the diagnosis of CCHS was confirmed for each case by the referring clinician. Sixty unrelated individuals who were phenotypically normal were recruited from the blood donors of the Istituto Gaslini and used as controls. DNA was extracted from peripheral blood lymphocytes according to standard procedures.

Our study protocol was approved by the ethics committee of the Department of Internal Medicine of the University of Genova and informed consent was obtained from all patients’ parents before study enrolment.

\subsection*{Mutational screening and molecular analysis}

To amplify the three coding regions, including intron-exon boundaries, we designed four PCR primer pairs (table 1) on the basis of the \textit{PHOX2B} sequence available in GenBank (accession number NT_022782) and using the Primer Express 2.0 software program.

Standard PCR reactions were set up in a total volume of 50 µL containing 200 ng of genomic DNA, 1 µM of primers, 1× buffer, 200 µM of each dNTP except for G, which was present at 150 µM+50 µM of 7-deaza-dGTP (Roche), and 1.25 U of Taq polymerase (PE Biosystems), and run for 35 cycles at 95˚C (45 s), the annealing temperature reported in table 1 (1 min), and 72 ˚C (1 min).

PCR reactions specific for GC rich templates were set up in a total volume of 50 µL containing 200 ng of genomic DNA, 400 nM primers, 1× of GC-RICH PCR buffer and 1 M GC-RICH resolution (GC-RICH PCR System, Roche), 200 µM of each dNTP and 2 U of GC-RICH PCR enzyme mix (Roche), and run for 30 cycles at 95 ˚C (30 s), 60 ˚C (30 s), and 72 ˚C (1 min).

PCR products were screened for mutations by direct sequencing, using the Big Dye Terminator cycle sequencing kit (Applied Biosystems) on an ABI 3100 DNA automated Sequencer. PCR products were column purified before sequencing (Microcon-PCR, Millipore).

The fifth primer pair reported in table 1 (145F+279R) was used to amplify a small portion of exon 3. 15 µl of this 120 bp PCR product were run on 8% (w/w) polyacrylamide gel, and DNA bands on the gel were developed using ethidium bromide.

We cloned the exon 3 PCR product (primers 10F+3.3R) using DNA from patient 23 as a template, into the TOPO TA vector (Invitrogen) following the manufacturer’s instructions. Plasmid DNA isolated from 35 clones was sequenced as described above.

A restriction cleavage with AvaII of the 627 bp exon 3 PCR amplifier (primers 10F+3.3R) of all patients, was carried out and analysed through 4% agarose gel electrophoresis.

\section*{RESULTS}

\subsection*{Mutation analysis of \textit{PHOX2B} gene in CCHS patients}

A mutation screening of the three exons spanning the entire coding sequence of the \textit{PHOX2B} gene has been performed in 27 CCHS patients, including three LOCHS cases, by direct DNA sequencing analysis. We found three nucleotide changes lying in the exon 3 and leading to out of frame translation (fig 1A).

One heterozygous C deletion and one heterozygous G insertion have been detected in two CCHS patients (27 and 21) within intervals c.614–618 and c.862–866 of the coding sequence, respectively (fig 1B). In the former case, the frame shift creates a premature stop codon and results in a 307 amino acid truncated protein, with the last 101 amino acids not belonging to the \textit{PHOX2B} sequence. In the latter case, the resulting frame shift relocates the stop codon 132 bp beyond its natural end, leading to disruption of 8.3% of the protein C-terminus. Analysis of the two patients’ parents has revealed that the c.614–618delC was inherited from the unaffected mother, while the c.862–866insG occurred de novo in the proband (data not shown). A 38 bp heterozygous deletion within exon 3, removing nucleotides 721–758 of the coding sequence and predicted to destroy the reading frame, has been found in the third patient (24) (fig 1B). His parents were found to carry no mutant \textit{PHOX2B} allele, following agarose gel analysis (fig 1C) and direct sequencing (data not shown) of the exon 3 amplification product.

\subsection*{Expansion of the alanine stretch in our CCHS patients}

To verify the presence of a possible expansion of the polyalanine tract in the exon 3 of a proportion of the 24 remaining non-mutant patients with CCHS, a 120 bp PCR product, resulting from amplification with primers 145F and 279R (table 1), was run on 8% acrylamide gel (fig 2A). Patients 8, 23, and 28 did show an extra band (with heteroduplex formation) corresponding to a size compatible with an expanded band. Indeed, DNA sequence of exon 3 had

\begin{table}[h]
\centering
\caption{Primer sequences used to screen all the \textit{PHOX2B} exons for mutations according to diagnostic criteria of the American Thoracic Society.}  
\begin{tabular}{lcccc}
\hline
Exon & Forward & Reverse & Temperature \(T_a\) \(^\circ\)C \\
\hline
1 & 35F: GGCCTGAGCCATCCAGAAGCT & 35R: CCTATATACGGGCGGAAAGGC & 62 \\
2 & 145F: AACCCGGCAAGGGCGGC & 279R: GAGCCCAGCCTTGTCCAGG & 65 \\
3 & 458 22F: GCACTGACCCGGACAGCACT & 3.3R: TACCCGCTCGCCCACTCG & 60 \\
4 & 627 10F: TGCTTCACCGTCTCTCCTC & 3.3R: TACCCGCTCGCCCACTCG & 60 \\
5 & 260 PH2F: TGCCGGCTGATTTGCTCAC & PH2R: AGCGGGGTCGGTTTCCAGG & 58 \\
6 & 320 35F: GGCTGAGCCATCCAGAACCT & 35R: CCTATATACGGGCGGAAAGGC & 62 \\
\hline
\end{tabular}
\end{table}
shown, in a proportion of CCHS DNAs including 2, 3, 7, 11, 16, 23, and 28, but not 8, very weak and variable evidences of the expansion of a number of alanines, ranging from 5 to 6 residues, with respect to the wild-type sequence. Such a putative expansion had the shape of a double shifted sequence displaying an intensity, in terms of height of the single peaks, varying from 10% to 30% of the main wild-type sequence, as shown in fig 2B, and could be observed, after either polyacrylamide gel electrophoresis or sequencing experiments, in seven individuals out of 27, and shown to recur from 25% to 100% of the times the DNA from a same individual was resequenced.

Cloning of an “alanine-expanded” allele
To confirm that the expanded sequence we observed did correspond to a germline expansion of the PHOX2B allele, carried by patients in their constitutive genomic DNA, we undertook the cloning of an exon 3 PCR product (primers 10F+3.3R) using DNA from patient 23, which had already shown evidence of alanine expansion, as a template. We used a single nucleotide polymorphism (SNP) identified by us during the mutational screening, a c870C>A change leading to a silent substitution in codon P290 of exon 3, to distinguish between the two alleles derived from DNA of patient 23, who had proved to be heterozygous for this variant (C/A). After amplification, we cloned the PCR product and sequenced 35 clones, each corresponding to one of the two single alleles originally present in the genomic DNA. Two combinations of polyalanine length and SNP alleles were obtained: the wild-type allele, containing 20 normal alanine residues, associated with the A variant in 28 clones, while the expanded allele, containing 25 alanine residues, associated with the C variant in the other seven clones. This has allowed us to verify that expansion was always associated with the same allele, as expected in case of a genomic expansion and to confirm a ratio of 1:4 of expanded:wild-type alleles which reflects the fact that longer (expanded) fragments are underrepresented in the PCR product. Moreover, the absence of different combinations of SNP alleles and polyalanine tracts allows the exclusion of both mosaicism in patient 23 and a possible artefact originated in vitro during DNA amplification.

Amplification of the exon 3 GC-rich region
The presence of a polyalanine expansion seems to result in the lack of amplification of the mutant allele. The sequence of the PHOX2B exon 3, and especially of its polyalanine tract, is highly GC rich (fig 1A). A probable explanation for the weak or absent amplification observed during the sequencing of our DNA samples is, therefore, that the presence of strong secondary structures might inhibit the action of the DNA polymerase during DNA amplification. In the attempt to overcome this problem we had already modified the standard amplification reaction by adding 10% glycerol or 7-Deaza-dGTP or increasing the annealing temperature, or both, but this might have not been sufficient to remove the impeding secondary structures resulting in false negative responses. So, to maximise the chance of correct amplification of both
alleles, we set up a PCR reaction making use of a couple of primers (10F + 3.3R) delimiting the whole exon 3 and of a system properly developed for GC rich templates. Direct sequencing of DNA amplification products thus obtained allowed us to detect polyalanine triplet expansions in samples which had previously shown neither variants nor weak double sequences. In particular, we identified 22 in frame changes leading to polyalanine expansions resulting from duplications, inserted in different positions of the polyalanine tract, ranging from 5 to 13 alanine residues and involving the last 15–39 bp before the insertion. An AvaII enzymatic digestion of the 627 bp exon 3 PCR amplimer allowed us to confirm presence of extra bands as shown in fig 3A. In particular, bands of 158 bp, 199 bp, and 270 bp, this latter containing the 20 alanine stretch, were obtained from enzymatic digestion of wild-type amplification products while expanded alleles could be recognised by the replacement of the largest fragment with an extra band of size variable from 285 to 309 bp (duplicates from 5 to 13 alanine residues). A summary of all the polyalanine expansions observed in our patients is reported in figure 3B. Polyalanine triplet expansion has also been detected in the affected siblings of two familial CCHS cases (4F and 11F). Inheritance by the asymptomatic mother could be proven for one of
nucleotides corresponding to CCHS patients. (A) Examples of various duplication lengths (+301 to +315 bp) obtained after enzymatic digestion with AvaII of the 627 bp PCR product of PHOX2B exon 3 (primers 10F to 3.3R) and migration on a 4% agarose gel (158 bp, 199 bp, and 270 bp are the expected, wild-type bands). The duplicated codons are shown in grey boxes. An asterisk is used to distinguish between different positions at which expansions of the same size have occurred.

![Diagram of duplicated codons](image.png)

**Figure 3** Expansion of the 20 alanine residues tract of PHOX2B in CCHS patients. (A) Examples of various duplication lengths (+15 to +39 nucleotides corresponding to +5 to +13 alanine residues) are provided and shown as extra bands of size variable from 285 to 309 bp, obtained after enzymatic digestion with AvaII of the 627 bp PCR product of PHOX2B exon 3 (primers 10F to 3.3R) and migration on a 4% agarose gel (158 bp, 199 bp, and 270 bp are the expected, wild-type bands). The duplicated codons are shown in grey boxes. An asterisk is used to distinguish between different positions at which expansions of the same size have occurred.

these, while, in the other case, the mother does not carry the Ala expansion and DNA from the father is not available (data not shown). The asymptomatic mother of a sporadic case with an 18 bp expansion of the alanine stretch has resulted in carrying the same mutant allele (data not shown). Patients 17 (LOCHS) and 25 (CCHS) showed neither mutations nor expansions of the polyalanine stretch in exon 3. Loss of heterozygosity could be excluded at a SNP locus identified by restriction enzymes CcI and Ssp1 in CCHS patients, which was found to be heterozygous (C/T). A summary of all the results is reported in table 2, along with clinical details of each patient.

None of the mutations found in the present study were present in 120 normal control chromosomes. On the other hand, in agreement with a mechanism of non-homologous recombination generating the polyalanine expansion in disease associated mutant alleles, and according to what had already been reported, an alanine triplet contraction was found in one control DNA.

**Selective amplification of the shortest allele in heterozygous individuals**

During our mutational screening we had already collected evidence to support the fact that in individuals heterozygous for length variants of the polyalanine region of the PHOX2B gene in 16 patients, and heterozygous frameshift mutations in two patients (62%). More recently, two similar studies have reported both polyalanine expansions and a few missense, nonsense and out-of-frame nucleotide changes in exon 3 of the PHOX2B gene, reflecting mutation frequencies of 50% and 98.5% in 10 and 67 patients respectively. Here, we report the identification of three heterozygous frameshift mutations and 22 in frame changes leading to polyalanine expansions of the PHOX2B gene in a total of 27 CCHS patients studied, including three LOCHS cases (93%). Two of the three frameshift mutations, a c.862–866insG and a 38 bp deletion of nucleotides c.721–758, have occurred de novo in two probands, while the third one, a novel c.614–618delC, was inherited from the asymptomatic mother. Of the remaining 24 patients, 20 have 5–7 extra alanine residues in the polyalanine stretch of PHOX2B exon 3, in addition to two other patients showing 11 and 13 polyalanine expansions. We have not detected expansions of fewer than five residues. Polyalanine triplet expansions have also been detected in the affected siblings of two familial CCHS cases. Inheritance from an asymptomatic parent could be proven for only one of these cases. Parents of sporadic cases have been found to carry no PHOX2B molecular changes with the exception of the asymptomatic mothers of two patients with CCHS, one already mentioned with the c.614–618delC, and the other with an expansion of 18 alanine residues, who demonstrated transmission of the mutant allele to their affected children. These observations provide a straightforward confirmation of simple dominant inheritance in CCHS with incomplete penetrance. So, the actual large proportion of sporadic cases might be explained by the very high mortality of patients with CCHS at a very young age or during the perinatal period until a few decades ago.

Two cases, one familial CCHS and one LOCHS, have been found to carry no PHOX2B molecular changes but we cannot exclude yet that defects either impairing correct expression or splicing of the gene, or residing outside the transcription unit (position effects) are present. Genetic heterogeneity could also explain the non-mutant patients.

As expected on the basis of data already reported, in addition to the respiratory phenotype each mutant patient shows a different and variable range of symptoms, mostly regarded as ANS dysfunctions (table 2). It is noticeable that the patient carrying the 38 bp deletion (patient 24) is the most seriously affected, with complete apnoea during sleep, severe hypoventilation during wakefulness and an extremely severe form of HSCR with total aganglionosis from duodenum to anus. Also patients 10 and 14, carrying the 11th and 13th largest polyalanine expansions respectively, show an extremely severe respiratory phenotype with the need of
ventilatory support during the day time, the latter patient presenting HSCR too. In the attempt to draw a genotype-phenotype correlation, we subdivided, on the basis of available information, patients into two groups according to

Table 2 Clinical and molecular characterisation of our CCHS patients

<table>
<thead>
<tr>
<th>Country of origin</th>
<th>Patients</th>
<th>Ventilation</th>
<th>ANSD</th>
<th>Gastro-intestinal symptoms</th>
<th>Mutation</th>
<th>Transmission</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>01</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>02</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>03</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>04</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>inherited</td>
</tr>
<tr>
<td>I</td>
<td>05</td>
<td>during sleep</td>
<td>O</td>
<td>decreased heart rate variability</td>
<td>dup21</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>06</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup21</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>07</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>08</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>de novo</td>
</tr>
<tr>
<td>I</td>
<td>09</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>inherited</td>
</tr>
<tr>
<td>I</td>
<td>10</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>G</td>
<td>11</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>G</td>
<td>12</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>?</td>
</tr>
<tr>
<td>G</td>
<td>13</td>
<td>24 hr</td>
<td>O</td>
<td>constipation</td>
<td>dup21</td>
<td>?</td>
</tr>
<tr>
<td>G</td>
<td>14</td>
<td>24 hr</td>
<td>O</td>
<td>constipation</td>
<td>dup39</td>
<td>?</td>
</tr>
<tr>
<td>G</td>
<td>15</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>16</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>17</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>18</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup18</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>19</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>20</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>G</td>
<td>21</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>22</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>23</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>24</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>25</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>26</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>27</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
<tr>
<td>I</td>
<td>28</td>
<td>during sleep</td>
<td>O</td>
<td>constipation</td>
<td>dup15</td>
<td>?</td>
</tr>
</tbody>
</table>

I, Italy; G, Germany; NL, The Netherlands; F, familial case; L0-CHS, late onset CHS; O, ocular anomalies.

* = distinguishes expansions of similar size but different localisation within the polyalanine stretch. 1 = Growth hormone deficiency; 2 = died at 4 months; 3 = tetralogy of Fallot; ne, not expanded

Non-random amplification of the shortest allele in heterozygous individuals. Wild-type and extra bands, obtained on a 4% agarose gel electrophoresis after enzymatic digestion with AvaII of a 627 bp fragment (primers 10F and 3.3R) are shown. Three DNA samples have been amplified using two different PCR methods: the standard protocol and the GC rich system protocol. Using the standard protocol, we could not observe any amplification from the wild-type allele in a control DNA bearing a contraction of seven alanine residues (c93), the expanded allele in a patient DNA with an expansion of five alanine residues (3), or the wild-type allele in the patient DNA with the 38 bp deletion (24). In contrast, using the GC rich system protocol, two different alleles could be amplified from each DNA sample thus confirming the heterozygous status of the three individuals at the polyalanine tract locus.

Figure 4 Non-random amplification of the shortest allele in heterozygous individuals. Wild-type and extra bands, obtained on a 4% agarose gel electrophoresis after enzymatic digestion with AvaII of a 627 bp fragment (primers 10F and 3.3R) are shown. Three DNA samples have been amplified using two different PCR methods: the standard protocol and the GC rich system protocol. Using the standard protocol, we could not observe any amplification from the wild-type allele in a control DNA bearing a contraction of seven alanine residues (c93), the expanded allele in a patient DNA with an expansion of five alanine residues (3), or the wild-type allele in the patient DNA with the 38 bp deletion (24). In contrast, using the GC rich system protocol, two different alleles could be amplified from each DNA sample thus confirming the heterozygous status of the three individuals at the polyalanine tract locus.

* = "GC rich" PCR protocol
c93 = control with 7 Ala-contraction
p3 = patient with 5 Ala-expansion
p24 = patient with 38nt deletion in the poly(Ala) tract

The 20 trinucleotide repeat of the polyalanine tract in PHOX2B is imperfect (fig 1). Therefore, replication slippage is unlikely and expansions are most probably caused by recombination between two mispaired alleles (unequal crossing over), as already proposed.22 Such a mispairing mechanism is expected to result in expansions as well as...
contractions, a phenomenon that has been reported so far only in healthy individuals, and observed also in our control set, in terms of the presence of a rare polymorphism having no effect on the phenotype.

The existence of a mutational hotspot in the region coding for the polyalanine domain of PHOX2B needs to be postulated since 92% of all mutations we detected so far in this gene leads to variations in the length of the polyalanine tract. There are at least nine genes in which alanine expansions have been shown to cause human disease. Moreover, 31 out of 98 sequences coding for polyalanine domains in the human genome have been found polymorphic, thus suggesting the opportunity of screening similar sequences in different pathologies. Although polyalanine tracts are common in transcription factors, neither their normal function nor the effects of their expansion are understood. Polyalanine tracts have been found in repression motifs of several proteins containing homeodomains and demonstrated, in some cases, to be responsible for the repression of target genes. In other cases, polyalanine tracts act as flexible spacer elements between functional domains. Thus, polyalanine expansions observed in PHOX2B may either directly interfere with protein-protein interactions, distort an essential secondary structure, or act as dominant negative factors. The correlation between phenotypic severity and expansion size observed in CCHS suggests that tracts of 25 or more polyalanines might confer a progressive gain of function to PHOX2B, a hypothesis which will require further studies.

During our study we have collected proof that polyalanine expansion corresponds to a PHOX2B allele carried by patients in their constitutive genomic DNA. Indeed, at first in our sequencing experiments alanine expansions had the appearance of an unclear background lying behind the normal DNA sequence in a small proportion of patients. Under the hypothesis that in individuals heterozygous for defects involving length changes of the polyalanine stretch of exon 3, the largest allele is always prone to unsuccessful amplification by DNA polymerase, and to avoid incorrect interpretation of the genotype of some patients and controls, we have developed a proper PCR protocol. Results reported in fig 4 have confirmed our hypothesis, showing different amplification outcomes when using different experimental protocols: when DNA amplification occurs under standard procedures, the shortest product is always observed while the largest amplifier can remain undetectable, as in the case of alanine expanded against wild-type alanine stretches and of wild-type alanine stretches against both the del58 allele and an alanine contracted tract in a control (fig 4). Such a misleading methodological aspect can cause mistakes in recording individuals’ genotypes and we therefore suggest great care when approaching PHOX2B mutational screening and especially for PHOX2B molecular diagnosis in relatives of affected children. Indeed, following observation of recurrence of PHOX2B defects and potential transmission of the CCHS phenotype to progeny, an accurate detection of PHOX2B mutations represents the ground for genetic counselling, which has become indispensable for couples with an affected child to determine the recurrence risk to a fetus.

In conclusion, PHOX2B is confirmed as the major gene in CCHS pathogenesis and autosomal dominant inheritance with reduced penetrance is now demonstrated. Moreover, a correlation between phenotypic severity and expansion length of the polyalanine tracts can be assumed and used to predict onset and progression of the disease in mutation carriers. Finally, molecular testing and genetic counselling has now become feasible, thus giving hopes to many families with CCHS.

REFERENCES


